Overview
- At week 36, 27.1% of patients on the combination achieved complete skin clearance and at least 10% weight loss versus 5.8% with Taltz alone, meeting the primary endpoint.
- In a key secondary outcome, complete skin clearance was reached by 40.6% on the combination compared with 29.0% on monotherapy.
- The TOGETHER-PsO trial enrolled 274 adults with an average BMI over 39 kg/m2, with most participants having high‑impact area involvement and roughly 25% body surface area affected.
- Adverse events were generally mild to moderate and consistent with each drug’s profile, including nausea, diarrhea and injection‑site reactions in the combination arm.
- Lilly said full results will be submitted for peer‑reviewed publication and regulatory discussions, noting Taltz now has data from two trials supporting use alongside an incretin therapy.